GlassScriptPhysician profile
John D Eatman
NPI 1942596523
$83,852.66
in general payments reported to CMS, 2019-2025
45 companies · $3,989 in 2025
The $3,989 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $5,605 · 2021: $12K · 2022: $12K · 2023: $14K · 2024: $12K · 2025: $3,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,737 · Consulting Fee: $3,675 · Travel and Lodging: $1,416 · Education: $9.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,755.00 |
| Food and Beverage | $6,737.42 |
| Consulting Fee | $3,675.00 |
| Travel and Lodging | $1,416.14 |
| Education | $9.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $38,420.06 | 2019-2024 | Ultomiris, Soliris |
| Alnylam Pharmaceuticals INC. | $34,413.87 | 2019-2025 | Amvuttra, Onpattro |
| Amgen INC. | $2,545.07 | 2023-2025 | Uplizna, Aimovig |
| Abbvie INC. | $1,654.67 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Argenx US, INC. | $1,444.14 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Akcea Therapeutics, INC. | $1,077.21 | 2019-2021 | |
| Mdd US Operations, LLC | $422.97 | 2023-2024 | Apokyn, Apokyn |
| Acadia Pharmaceuticals INC | $398.47 | 2023-2025 | Nuplazid |
| Pfizer INC. | $397.09 | 2023-2024 | |
| Biogen, INC. | $348.33 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Amneal Pharmaceuticals LLC | $322.25 | 2023-2025 | Rytary, Crexont |
| Lilly USA, LLC | $198.20 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Ucb, INC. | $197.50 | 2023-2025 | Rystiggo, Briviact |
| Celgene Corporation | $194.62 | 2023-2025 | Zeposia |
| Emd Serono, INC. | $193.40 | 2023-2025 | Mavenclad, Mavenclad |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $162.12 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $150.76 | 2021-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $126.28 | 2024 | Wainua |
| Kyowa Kirin, INC. | $110.25 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $86.94 | 2023-2024 | Nuedexta, Rexulti |
| Ultragenyx Pharmaceutical INC. | $83.03 | 2023-2024 | Dojolvi |
| Catalyst Pharmaceuticals, INC. | $76.96 | 2023-2025 | Firdapse |
| Upsher-Smith Laboratories LLC | $69.11 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.34 | 2024-2025 | Hyqvia |
| Boston Scientific Corporation | $57.94 | 2024 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $55.60 | 2023 | Adlarity |
| Hospira, INC. | $47.23 | 2024 | |
| Novartis Pharmaceuticals Corporation | $46.59 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $40.32 | 2023-2024 | Epidiolex |
| Impel Pharmaceuticals INC. | $39.81 | 2023 | Trudhesa |
| Abbott Laboratories | $39.72 | 2024 | Infinity |
| Teva Pharmaceuticals USA, INC. | $39.58 | 2024 | Ajovy |
| Sk Life Science, INC. | $37.69 | 2023-2025 | |
| Axsome Therapeutics, INC. | $35.71 | 2025 | Symbravo |
| Octapharma USA, INC. | $34.68 | 2023 | Octagam Immune Globulin (Human), Panzyga |
| Neurelis, INC. | $31.44 | 2025 | Valtoco |
| Sumitomo Pharma America, INC. | $29.11 | 2023-2024 | Aptiom |
| Genzyme Corporation | $26.23 | 2023 | |
| Eisai INC. | $25.61 | 2025 | |
| Averitas Pharma INC. | $24.50 | 2023 | Qutenza |
| Horizon Therapeutics Plc | $22.85 | 2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $20.74 | 2025 | Xeomin |
| Mallinckrodt Hospital Products INC. | $18.39 | 2025 | Acthar |
| Grifols USA, LLC | $14.39 | 2024 | Gamunex-C |
| Neurocrine Biosciences, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eatman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.